#United States #Medical Device #WuXi AppTec #Toledo #NAMSA

NAMSA Completes Acquisition of WuXi AppTec's U.S. Medical Device Testing Operations

In a significant move to bolster its presence in the medical technology sector, NAMSA, a renowned U.S.-based firm specializing in MedTech testing, clinical, and regulatory consulting, recently reported the completion of its acquisition of WuXi AppTec's U.S. medical device testing operations on February 28. This strategic acquisition brings together two industry leaders in medical device biological safety testing, aiming to provide enhanced services to over 4,000 manufacturers globally.

Lisa Olson, NAMSA's Senior Vice President of Global Laboratory Services, expressed her excitement about the merger, stating, "Together, we now have unmatched scientific expertise in biocompatibility, microbiology, preclinical, and extractables and leachables testing. This integration allows us to expand our operations with greater lab capacity and a more extensive team of scientists, ensuring we can support a wider variety of medical devices than ever before."

The implications of this acquisition are vast. With WuXi AppTec's established medical device testing facilities now under the NAMSA umbrella, the combined entity not only enhances its resources but also aims to refine its testing strategies tailored to specific devices and regulatory frameworks. This will inevitably facilitate a more streamlined approach for clients navigating the complexities of medical technology development.

Since 2021, NAMSA has actively diversified its offerings, having acquired six companies focused on preclinical and clinical research, positioning itself as a leading contract research organization (CRO) dedicated to MedTech. Brian Smith, NAMSA's recently appointed CEO, highlighted this acquisition as a key component of their broader strategy to enhance their service offerings. He remarked, "Our goal is to solidify our position as the go-to resource for manufacturers aiming to bring innovative, life-saving technologies to market while maintaining the high standards of client-focused service that NAMSA is known for."

Established in 1967, NAMSA has made significant contributions to improving healthcare through its extensive knowledge and expertise in the medical device sector. Their commitment to accelerating product development encompasses a wide array of services, from preclinical and clinical research to regulatory compliance and medical device testing. As a trusted partner in the MedTech field, NAMSA continues to pave the way for successful commercialization outcomes for its clients.

With this acquisition of WuXi AppTec's U.S. operations, NAMSA is uniquely poised to expand its reach and reinforce its commitment to serving the medical device industry effectively. The integration of diverse expertise and resources is expected to shape the future of medical device testing and consulting, ultimately benefiting manufacturers and advancing healthcare innovations worldwide. For more information about NAMSA and its offerings, visit namsa.com.